FIELD: biotechnology.
SUBSTANCE: described is a group of inventions involving a pharmaceutical combination for treating cancer wherein CD20 is expressed and using the pharmaceutical combination for preparing a drug for treating cancer wherein CD20 is expressed. Pharmaceutical combination consists of rituximab and BTK inhibitor, which is 6-amino-9-[(3R)-1-(2-butinoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or a salt thereof, in a synergistically effective amount, where the amount of rituximab ranges from 0.1 to 50 mg/kg, and amount 6-amino-9-[(3R)-1-(2-butinoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or its salt ranges from 1 mcg/kg to 50 mg/kg.
EFFECT: invention extends the range of agents for treating cancer in which CD20 is expressed.
5 cl, 5 dwg, 7 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED ANTIGEN-BINDING MOLECULES WITH CHANGED CELL SIGNAL ACTIVITY | 2006 |
|
RU2547931C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| DOSING STRATEGY REDUCING CYTOKINE RELEASE SYNDROME FOR CD3/C20 BISPECIFIC ANTIBODIES | 2019 |
|
RU2799529C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
| COMBINATION OF CD19 ANTIBODY AND BRUTON TYROSINE KINASE INHIBITOR AND THEIR APPLICATION | 2016 |
|
RU2756010C2 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
